Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs

Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakeholders on addressing these costs. We examined 982 pre...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2019-11, Vol.14 (11), p.e0225109-e0225109
Main Authors: Murimi-Worstell, Irene B, Ballreich, Jeromie M, Seamans, Marissa J, Alexander, G Caleb
Format: Article
Language:English
Subjects:
Backup software
Biology and Life Sciences
Competition
Costs
Drug approval
Drug Costs
Drugs
Drugs, Generic - economics
Economic aspects
Evaluation
Generic drugs
Humans
Medicine and Health Sciences
Pharmaceuticals
Pharmacology
Pharmacopoeias as Topic
Prescription Drugs - economics
Prescriptions (Drugs)
Product development
Social Sciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c593t-7f0dcef3d6169ae4a151e208facf4b54db2bf3c5d35099055bb0979d5f1c59ed3
cites cdi_FETCH-LOGICAL-c593t-7f0dcef3d6169ae4a151e208facf4b54db2bf3c5d35099055bb0979d5f1c59ed3
container_end_page e0225109
container_issue 11
container_start_page e0225109
container_title PloS one
container_volume 14
creator Murimi-Worstell, Irene B
Ballreich, Jeromie M
Seamans, Marissa J
Alexander, G Caleb
description Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakeholders on addressing these costs. We examined 982 prescription drugs approved by U.S Food and Drug Administration since 1982 to examine the association between U.S. Pharmacopeia (USP) standards, generic entry and prescription costs. The presence of a USP drug product monograph was not associated with the time to the third generic entrant or with the likelihood of having a generic competitor. However, on average, drugs with USP drug product monographs had approximately fifty percent more generic manufacturers in the U.S. than their counterparts after accounting for factors such as market volume, age, route of administration and vintage. This greater competition was associated with an approximate savings of $6.22 billion in 2016, suggesting that USP drug product monographs may play an important role in promoting pharmaceutical competition and reducing prescription drug costs.
doi_str_mv 10.1371/journal.pone.0225109
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2314030302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A605567733</galeid><doaj_id>oai_doaj_org_article_1e91ec8cbda3424db9a0cab0ea3098b2</doaj_id><sourcerecordid>A605567733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c593t-7f0dcef3d6169ae4a151e208facf4b54db2bf3c5d35099055bb0979d5f1c59ed3</originalsourceid><addsrcrecordid>eNptkl1r2zAUhs3YWLtu_2Bsht10sGSSZcnRzSCUfRQKK3S5FsfSsaNgS57kbPTfT27c0oyiC4mj9zzngzfL3lKypKyin3d-Hxx0y8E7XJKi4JTIZ9kplaxYiIKw54_eJ9mrGHeEcLYS4mV2wmhFS1mK02y7jtFrC6P1Lq9x_Ivo8s1Nfr2F0IP2A1rIzzc31x_z3jvfBhi2eRzBGQgmfspbdBisztGN4TZP4XwIGHWwwx3RhH2bax_H-Dp70UAX8c18n2Wbb19_XfxYXP38fnmxvlpoLtm4qBpiNDbMCCokYAmUUyzIqgHdlDUvTV3UDdPcME6kJJzXNZGVNLyhCYCGnWXvD9yh81HNS4qqYLQkLJ0iKS4PCuNhp4Zgewi3yoNVdwEfWgVhtLpDRVFS1CtdG2BlkYpLIBpqgsCIXNUT68tcbV_3mDpPa4DuCHr84-xWtf6PEiuemmcJcD4Dgv-9xziq3kaNXQcO_f7Qd8EFEZP0w3_Sp6ebVS2kAaxrfKqrJ6hai1RSVBWbWMsnVOkY7K1Ojmpsih8llIcEHXyMAZuHGSlRkx_vm1GTH9Xsx5T27vF-HpLuDcj-AQaz3pM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2314030302</pqid></control><display><type>article</type><title>Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs</title><source>NCBI_PubMed Central（免费）</source><source>Publicly Available Content Database</source><creator>Murimi-Worstell, Irene B ; Ballreich, Jeromie M ; Seamans, Marissa J ; Alexander, G Caleb</creator><contributor>Degtyar, Vadim E.</contributor><creatorcontrib>Murimi-Worstell, Irene B ; Ballreich, Jeromie M ; Seamans, Marissa J ; Alexander, G Caleb ; Degtyar, Vadim E.</creatorcontrib><description>Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakeholders on addressing these costs. We examined 982 prescription drugs approved by U.S Food and Drug Administration since 1982 to examine the association between U.S. Pharmacopeia (USP) standards, generic entry and prescription costs. The presence of a USP drug product monograph was not associated with the time to the third generic entrant or with the likelihood of having a generic competitor. However, on average, drugs with USP drug product monographs had approximately fifty percent more generic manufacturers in the U.S. than their counterparts after accounting for factors such as market volume, age, route of administration and vintage. This greater competition was associated with an approximate savings of $6.22 billion in 2016, suggesting that USP drug product monographs may play an important role in promoting pharmaceutical competition and reducing prescription drug costs.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0225109</identifier><identifier>PMID: 31714946</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Backup software ; Biology and Life Sciences ; Competition ; Costs ; Drug approval ; Drug Costs ; Drugs ; Drugs, Generic - economics ; Economic aspects ; Evaluation ; Generic drugs ; Humans ; Medicine and Health Sciences ; Pharmaceuticals ; Pharmacology ; Pharmacopoeias as Topic ; Prescription Drugs - economics ; Prescriptions (Drugs) ; Product development ; Social Sciences</subject><ispartof>PloS one, 2019-11, Vol.14 (11), p.e0225109-e0225109</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Murimi-Worstell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Murimi-Worstell et al 2019 Murimi-Worstell et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c593t-7f0dcef3d6169ae4a151e208facf4b54db2bf3c5d35099055bb0979d5f1c59ed3</citedby><cites>FETCH-LOGICAL-c593t-7f0dcef3d6169ae4a151e208facf4b54db2bf3c5d35099055bb0979d5f1c59ed3</cites><orcidid>0000-0002-8442-4286</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2314030302/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2314030302?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31714946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Degtyar, Vadim E.</contributor><creatorcontrib>Murimi-Worstell, Irene B</creatorcontrib><creatorcontrib>Ballreich, Jeromie M</creatorcontrib><creatorcontrib>Seamans, Marissa J</creatorcontrib><creatorcontrib>Alexander, G Caleb</creatorcontrib><title>Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakeholders on addressing these costs. We examined 982 prescription drugs approved by U.S Food and Drug Administration since 1982 to examine the association between U.S. Pharmacopeia (USP) standards, generic entry and prescription costs. The presence of a USP drug product monograph was not associated with the time to the third generic entrant or with the likelihood of having a generic competitor. However, on average, drugs with USP drug product monographs had approximately fifty percent more generic manufacturers in the U.S. than their counterparts after accounting for factors such as market volume, age, route of administration and vintage. This greater competition was associated with an approximate savings of $6.22 billion in 2016, suggesting that USP drug product monographs may play an important role in promoting pharmaceutical competition and reducing prescription drug costs.</description><subject>Backup software</subject><subject>Biology and Life Sciences</subject><subject>Competition</subject><subject>Costs</subject><subject>Drug approval</subject><subject>Drug Costs</subject><subject>Drugs</subject><subject>Drugs, Generic - economics</subject><subject>Economic aspects</subject><subject>Evaluation</subject><subject>Generic drugs</subject><subject>Humans</subject><subject>Medicine and Health Sciences</subject><subject>Pharmaceuticals</subject><subject>Pharmacology</subject><subject>Pharmacopoeias as Topic</subject><subject>Prescription Drugs - economics</subject><subject>Prescriptions (Drugs)</subject><subject>Product development</subject><subject>Social Sciences</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1r2zAUhs3YWLtu_2Bsht10sGSSZcnRzSCUfRQKK3S5FsfSsaNgS57kbPTfT27c0oyiC4mj9zzngzfL3lKypKyin3d-Hxx0y8E7XJKi4JTIZ9kplaxYiIKw54_eJ9mrGHeEcLYS4mV2wmhFS1mK02y7jtFrC6P1Lq9x_Ivo8s1Nfr2F0IP2A1rIzzc31x_z3jvfBhi2eRzBGQgmfspbdBisztGN4TZP4XwIGHWwwx3RhH2bax_H-Dp70UAX8c18n2Wbb19_XfxYXP38fnmxvlpoLtm4qBpiNDbMCCokYAmUUyzIqgHdlDUvTV3UDdPcME6kJJzXNZGVNLyhCYCGnWXvD9yh81HNS4qqYLQkLJ0iKS4PCuNhp4Zgewi3yoNVdwEfWgVhtLpDRVFS1CtdG2BlkYpLIBpqgsCIXNUT68tcbV_3mDpPa4DuCHr84-xWtf6PEiuemmcJcD4Dgv-9xziq3kaNXQcO_f7Qd8EFEZP0w3_Sp6ebVS2kAaxrfKqrJ6hai1RSVBWbWMsnVOkY7K1Ojmpsih8llIcEHXyMAZuHGSlRkx_vm1GTH9Xsx5T27vF-HpLuDcj-AQaz3pM</recordid><startdate>20191112</startdate><enddate>20191112</enddate><creator>Murimi-Worstell, Irene B</creator><creator>Ballreich, Jeromie M</creator><creator>Seamans, Marissa J</creator><creator>Alexander, G Caleb</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8442-4286</orcidid></search><sort><creationdate>20191112</creationdate><title>Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs</title><author>Murimi-Worstell, Irene B ; Ballreich, Jeromie M ; Seamans, Marissa J ; Alexander, G Caleb</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c593t-7f0dcef3d6169ae4a151e208facf4b54db2bf3c5d35099055bb0979d5f1c59ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Backup software</topic><topic>Biology and Life Sciences</topic><topic>Competition</topic><topic>Costs</topic><topic>Drug approval</topic><topic>Drug Costs</topic><topic>Drugs</topic><topic>Drugs, Generic - economics</topic><topic>Economic aspects</topic><topic>Evaluation</topic><topic>Generic drugs</topic><topic>Humans</topic><topic>Medicine and Health Sciences</topic><topic>Pharmaceuticals</topic><topic>Pharmacology</topic><topic>Pharmacopoeias as Topic</topic><topic>Prescription Drugs - economics</topic><topic>Prescriptions (Drugs)</topic><topic>Product development</topic><topic>Social Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murimi-Worstell, Irene B</creatorcontrib><creatorcontrib>Ballreich, Jeromie M</creatorcontrib><creatorcontrib>Seamans, Marissa J</creatorcontrib><creatorcontrib>Alexander, G Caleb</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murimi-Worstell, Irene B</au><au>Ballreich, Jeromie M</au><au>Seamans, Marissa J</au><au>Alexander, G Caleb</au><au>Degtyar, Vadim E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-11-12</date><risdate>2019</risdate><volume>14</volume><issue>11</issue><spage>e0225109</spage><epage>e0225109</epage><pages>e0225109-e0225109</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakeholders on addressing these costs. We examined 982 prescription drugs approved by U.S Food and Drug Administration since 1982 to examine the association between U.S. Pharmacopeia (USP) standards, generic entry and prescription costs. The presence of a USP drug product monograph was not associated with the time to the third generic entrant or with the likelihood of having a generic competitor. However, on average, drugs with USP drug product monographs had approximately fifty percent more generic manufacturers in the U.S. than their counterparts after accounting for factors such as market volume, age, route of administration and vintage. This greater competition was associated with an approximate savings of $6.22 billion in 2016, suggesting that USP drug product monographs may play an important role in promoting pharmaceutical competition and reducing prescription drug costs.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31714946</pmid><doi>10.1371/journal.pone.0225109</doi><orcidid>https://orcid.org/0000-0002-8442-4286</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2019-11, Vol.14 (11), p.e0225109-e0225109
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2314030302
source NCBI_PubMed Central（免费）; Publicly Available Content Database
subjects Backup software
Biology and Life Sciences
Competition
Costs
Drug approval
Drug Costs
Drugs
Drugs, Generic - economics
Economic aspects
Evaluation
Generic drugs
Humans
Medicine and Health Sciences
Pharmaceuticals
Pharmacology
Pharmacopoeias as Topic
Prescription Drugs - economics
Prescriptions (Drugs)
Product development
Social Sciences
title Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T04%3A03%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20US%20Pharmacopeia%20(USP)%20monograph%20standards,%20generic%20entry%20and%20prescription%20drug%20costs&rft.jtitle=PloS%20one&rft.au=Murimi-Worstell,%20Irene%20B&rft.date=2019-11-12&rft.volume=14&rft.issue=11&rft.spage=e0225109&rft.epage=e0225109&rft.pages=e0225109-e0225109&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0225109&rft_dat=%3Cgale_plos_%3EA605567733%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c593t-7f0dcef3d6169ae4a151e208facf4b54db2bf3c5d35099055bb0979d5f1c59ed3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2314030302&rft_id=info:pmid/31714946&rft_galeid=A605567733&rfr_iscdi=true